期刊
CURRENT MEDICINAL CHEMISTRY
卷 26, 期 16, 页码 2844-2864出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/0929867325666180201095743
关键词
Pulmonary arterial hypertension; macitentan; riociguat; selexipag; initial combination therapy; gene therapy; serotonin; inflammation; immunity; metabolism; pulmonary arterial denervation
Despite recent advances in Pulmonary Arterial Hypertension (PAH) treatment, this condition is still characterized by an extremely poor prognosis. In this review, we discuss the use of newly-approved drugs for PAH treatment with already known mechanisms of action (macitentan), innovative targets (riociguat and selexipag), and novel therapeutic approaches with initial up-front combination therapy. Secondly, we describe new potential signaling pathways and investigational drugs with promising role in the treatment of PAH.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据